Search alternatives:
significant caused » significant cause (Expand Search), significant causal (Expand Search), significant based (Expand Search)
caused decreased » causes increased (Expand Search), use decreased (Expand Search), marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
significant caused » significant cause (Expand Search), significant causal (Expand Search), significant based (Expand Search)
caused decreased » causes increased (Expand Search), use decreased (Expand Search), marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
149
-
150
-
151
-
152
Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1.
Published 2024“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10<sup>−6</sup>, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 295 units from 5 recording sessions, n<sub>APP/PS1</sub> = 167 units from 4 recording sessions). …”
-
153
-
154
-
155
-
156
Baseline Characteristics of Study Participants Stratified by Sleep Duration Categories.
Published 2025Subjects: -
157
Incidence of New-Onset Cardiovascular Disease in 2018 Follow-up by Sleep Duration Groups.
Published 2025Subjects: -
158
Subgroup Analysis of Sleep Duration and Cardiovascular Disease Risk in Type 2 Diabetes Patients.
Published 2025Subjects: -
159
-
160